At the news
? NEUTRALIMPACT 2/10 144 filed Nov 12, 2026 at 16:19 ET
Director Kristine Ball filed a Form 144 notice of intent to sell 18,000 shares of Oruka Therapeutics common stock, with an estimated aggregate market value of approximately $1.93 million. The shares were acquired via stock option exercise on the same date. The sale represents a modest portion of the director's holdings and is not unusual for a director-level insider.
- Kristine Ball, a director, filed Form 144 to sell 18,000 shares of common stock.
- Estimated aggregate market value of the proposed sale is $1,929,060.
- Shares were acquired on 11/12/2026 via exercise of stock options from the issuer.
- The proposed sale date is 11/12/2026, the same day as the filing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access